Citadel Advisors’s American Oncology Network, Inc. Class A Common Stock AONC Stock Holding History

Citadel Advisors’s Portfolio AONC Stock Details AONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-750,000	Closed	-$7.53M	–	15755
2022 Q4	$7.53M	Sell	750,000 -405	-0.1%	-$4.02K	﹤0.01%	3214
2022 Q3	$7.37M	Sell	750,405 -226	-0%	-$2.22K	﹤0.01%	3224
2022 Q2	$7.34M	Buy	750,631 +609	+0.1%	+$5.96K	﹤0.01%	3122
2022 Q1	$7.32M	Buy	750,022 +22	+0%	+$214	﹤0.01%	3470
2021 Q4	$7.27M	Buy	+750,000	New	+$7.3M	﹤0.01%	3641

Other funds holding AONC

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

MSU

Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Citadel Advisors's AONC Position: Q1 2023 in Review

Citadel Advisors sold out of American Oncology Network, Inc. Class A Common Stock (AONC) in Q1 2023, closing a stake of 750,000 shares — an estimated $7.53M sold.

Citadel Advisors first reported a position in AONC in Q4 2021 and held it in 5 quarters. The position peaked at $7.53M in Q4 2022. 13 funds tracked by Wall St. Rank hold AONC as of Q1 2023.

Citadel Advisors reported no remaining American Oncology Network, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 750,000 American Oncology Network, Inc. Class A Common Stock shares in Q1 2023, an estimated $7.53M.
Citadel Advisors first reported a position in American Oncology Network, Inc. Class A Common Stock in Q4 2021 and held it in 5 quarters.
Citadel Advisors's American Oncology Network, Inc. Class A Common Stock position peaked at $7.53M in Q4 2022.
13 funds tracked by Wall St. Rank held American Oncology Network, Inc. Class A Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.